Zoetis Inc. $ZTS Shares Purchased by Highland Capital Management LLC

Highland Capital Management LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 5.3% in the second quarter, Holdings Channel.com reports. The firm owned 39,635 shares of the company’s stock after buying an additional 2,006 shares during the period. Highland Capital Management LLC’s holdings in Zoetis were worth $6,181,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Nova Wealth Management Inc. bought a new position in Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC bought a new position in Zoetis during the 1st quarter worth approximately $27,000. Saudi Central Bank bought a new position in Zoetis during the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC lifted its holdings in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after buying an additional 88 shares during the last quarter. Finally, ORG Partners LLC lifted its holdings in Zoetis by 56.8% during the 2nd quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after buying an additional 84 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 0.0%

Shares of NYSE ZTS opened at $146.45 on Friday. The company has a market cap of $64.91 billion, a price-to-earnings ratio of 25.21, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock’s 50 day simple moving average is $149.79 and its 200 day simple moving average is $155.08.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on ZTS shares. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a report on Saturday, September 27th. Argus reaffirmed a “buy” rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and cut their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.